Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

UNITED STATES: FDA Approves Hepatitis B Viral DNA Test
The first hepatitis B virus (HBV) nucleic acid test to measure the amount of viral DNA in a patient's blood has won Food and Drug Administration approval. 'The COBAS TaqMan HBV Test extracts and then amplifies sections of viral DNA from human plasma or

Toll rises to 121 in Uganda hepatitis epidemic
A hepatitis E epidemic has killed 121 people in northern Uganda, where it erupted in October last year, a health ministry official said Thursday. A diagram showing the hepatitis C virus © AFP/File KAMPALA (AFP) - The outbreak has mainly affected

Roche Molecular Diagnostics Wins FDA OK for Hepatitis B Test
A hepatitis B viral load test, developed by Roche Molecular Diagnostics in Pleasanton, was approved by the Food and Drug Administration.

UPDATES AND COMMENTARY RSS Feed

HCV Genotype 1 Viral Loads Decline
A six-month follow-up to Intercell's Phase II trial of their Hepatitis C vaccine with a topical toll-like receptor agonist showed a significant reduction in viral load. While data from two weeks after the vaccination series showed promise, participants with Hepatitis...

Former Anti-Itch Drug Useful Against Hep C
California scientists have found that an old antihistamine drastically reduces Hepatitis C viral replication....

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

New Warnings Placed On Rebetron Hepatitis Therapy

PHILADELPHIA, PA -- Feb. 18, 1999 -- After just six months on the market, revised safety information tells doctors and patients to be even more cautious in the use of combination therapy to treat hepatitis C.

A black box warning in the revised prescribing information for Schering-Plough’s Rebetron(TM) warns that patients and their partners must use two forms of contraception because of the risk of birth defects or loss of a pregnancy from combination therapy.

Even if only one partner is taking Rebetron, both members of the couple need to use adequate contraception during therapy and for six months after the end of treatment.

Rebetron is a combination of Rebetol(R) (ribavirin, USP) Capsules and Intron(R) A (interferon alfa-2b, recombinant) Injection. It is the ribavirin component that is blamed for the risks to the fetus.

The United States Food and Drug Administration recently approved Rebetron combination therapy for patients with hepatitis C who had never been treated before. Previously, only people who had failed a previous treatment could receive Rebetron. But at the same time as it allowed wider use, the FDA increased the warnings to reflect the danger of the combination therapy during pregnancy. Ever since Rebetron was first approved, Schering-Plough has maintained a registry to track people on the therapy who become pregnant.

Dr. Enrique Molina, a hepatologist and assistant professor of clinical medicine at the Center for Liver Diseases, University of Miami, FL., says no patients with pregnancy-related complications from Rebetron treatment have been referred to his practice yet. However, he feels physicians need to counsel patients carefully before prescribing Rebetron.

"If a patient is not willing to practice strict contraception, that's certainly a contraindication for ribavirin. It makes a bigger difference for younger patients than for older ones," he said. "Many of our patients are 40 or 50 and already practising contraception so it's not a big issue for them, but for those that are younger, it's definitely an important point for physicians to stress."

table Of Contents

Hepatitis Central

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 07 Sep 2008